CD4 and neoplasm: C2 was the subtype with the weakest metabolic activity and the worst prognosis, which tends to be vascular invasion, poorly differentiated tumor, higher AFP level (>300 ng/ml), advanced stage, and age <65 years), with massive infiltrative events of activated CD4 T cells, mast cells, regulatory T cells (Tregs), and Th2 cells.